Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$1.73
+17.7%
$1.42
$1.09
$7.66
$122.84M2.931.38 million shs1.28 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$0.62
+9.5%
$0.52
$0.34
$3.46
$53.10M1.77513,075 shs3.50 million shs
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$0.36
$0.05
$11.78
$5.07M1.2434.54 million shs23.06 million shs
Opthea Limited stock logo
OPT
Opthea
$3.41
+7.2%
$3.41
$1.79
$6.30
$524.84M1.1226,986 shs3,000 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
+17.69%+40.08%+15.72%-26.69%-65.05%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
+9.47%+14.15%+17.84%-5.97%-79.46%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00%0.00%0.00%0.00%0.00%
Opthea Limited stock logo
OPT
Opthea
0.00%0.00%0.00%-2.85%+32.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.1027 of 5 stars
3.32.00.00.02.51.70.6
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.3249 of 5 stars
3.53.00.00.01.61.70.6
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Opthea Limited stock logo
OPT
Opthea
0.5963 of 5 stars
2.10.00.00.00.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.50
Moderate Buy$12.00593.64% Upside
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.00
Buy$4.20581.49% Upside
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00
N/AN/AN/A
Opthea Limited stock logo
OPT
Opthea
2.17
Hold$1.33-60.90% Downside

Current Analyst Ratings Breakdown

Latest OPT, IPSC, NSTG, and CCCC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
4/3/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $2.00
3/28/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Opthea Limited stock logo
OPT
Opthea
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$12.00 ➝ $2.00
3/25/2025
Opthea Limited stock logo
OPT
Opthea
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$12.00 ➝ $1.00
3/25/2025
Opthea Limited stock logo
OPT
Opthea
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Underperform$8.00 ➝ $1.00
3/24/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $7.00
3/24/2025
Opthea Limited stock logo
OPT
Opthea
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/24/2025
Opthea Limited stock logo
OPT
Opthea
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/21/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
3/20/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$4.00 ➝ $2.00
(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$39.78M3.09N/AN/A$4.07 per share0.43
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$114.90M0.46N/AN/A$3.06 per share0.20
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$127.26M0.00N/AN/A$0.98 per share0.00
Opthea Limited stock logo
OPT
Opthea
$87.67K5,986.77N/AN/A($0.56) per share-6.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$132.49M-$1.47N/AN/AN/A-313.35%-42.45%-27.55%7/30/2025 (Estimated)
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$136.67M-$0.29N/AN/AN/A-4,837.73%-61.66%-31.78%8/14/2025 (Estimated)
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
-$159.54M-$3.53N/AN/AN/A-102.44%-548.25%-53.79%N/A
Opthea Limited stock logo
OPT
Opthea
-$220.24MN/A0.00N/AN/AN/AN/AN/AN/A

Latest OPT, IPSC, NSTG, and CCCC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million
5/7/2025Q1 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million
3/19/2025Q4 2024
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/A
Opthea Limited stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
6.31
6.31
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
10.39
10.39
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
2.73
2.02
Opthea Limited stock logo
OPT
Opthea
N/A
2.94
2.94

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
Opthea Limited stock logo
OPT
Opthea
55.95%

Insider Ownership

CompanyInsider Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
6.80%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
3.10%
Opthea Limited stock logo
OPT
Opthea
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.01 million64.55 millionOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
17086.16 million79.25 millionOptionable
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
55048.12 million46.63 millionOptionable
Opthea Limited stock logo
OPT
Opthea
8153.91 million148.98 millionNot Optionable

Recent News About These Companies

Opthea Limited stock logo
Opthea (NASDAQ:OPT) Trading Up 7.2% - What's Next?
Opthea to lay off approximately 65% of company
Opthea Ends Development of Sozinibercept in Wet AMD
Opthea terminates COAST trial, announces ShORe trial misses endpoint

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$1.73 +0.26 (+17.69%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$1.70 -0.03 (-1.50%)
As of 06/6/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$0.62 +0.05 (+9.47%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$0.63 +0.02 (+2.55%)
As of 06/6/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

NanoString Technologies stock logo

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Opthea stock logo

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)
As of 06/5/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.